問卷

TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Nephrology

Division of Neurology

Kaohsiung Veterans General Hosptial

Division of Orthopedics

Chi Mei Medical Center

Division of Infectious Disease

更新時間:2023-09-19

陳俊宇Chen, Chun-Yu
  • Principal Investigator
  • Clinical Trial Experience (year) 15 years 6 個月
  • shilewu@gmail.com

篩選

List

27Cases

2024-04-01 - 2025-04-30

Phase I

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-02-25 - 2024-06-05

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2021-08-31 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
18Sites

Not yet recruiting9Sites

Recruiting9Sites

2018-02-01 - 2024-12-31

Phase II

Active
A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
  • Condition/Disease

    Parkinson′s disease dementia

  • Test Drug

    ceftriaxone

Participate Sites
11Sites

Recruiting5Sites

Terminated5Sites

2023-12-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults with IgA Nephropathy (The BEYOND Study)
  • Condition/Disease

    Adults with IgA Nephropathy

  • Test Drug

    injection

Participate Sites
8Sites

Recruiting8Sites

2023-07-01 - 2024-12-17

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2022-12-31 - 2024-01-04

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-12-01 - 2029-06-30

Phase III

Active
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study)
  • Condition/Disease

    IgA Nephropathy 、Immunoglobulin A Nephropathy

  • Test Drug

    皮下注射劑

Participate Sites
8Sites

Recruiting8Sites

2022-08-01 - 2029-06-04

Phase II/III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2 3